Retractable Technologies, Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. The company designs, manufactures, and markets safety syringes and other medical products. The unaudited results should be read with its 2021 Form 10-K.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net sales | $14.34 million | $42.50 million | $59.08 million | $92.57 million |
| Gross profit / margin | $3.65 million / 25.4% | $19.64 million / 46.2% | $19.21 million / 32.5% | $47.64 million / 51.5% |
| Operating income (loss) | ($2.06 million) | $12.67 million | $7.66 million | $36.10 million |
| Net income (loss) | ($3.64 million) | $10.66 million | $3.97 million | $28.62 million |
| Basic EPS | ($0.11) | $0.31 | $0.12 | $0.84 |
- Q2 sales fell 66.3% year over year; first-half sales fell 36.2%. First-half operating cash flow was $12.95 million, down from $31.51 million.
- Cash was $20.44 million at June 30, down from $29.16 million at year-end. Current assets were $87.94 million and current liabilities $16.25 million. The company also held $26.87 million in marketable debt and equity securities.
- Total liabilities were $91.78 million, including $73.87 million in long-term TIA-related liabilities. Long-term debt, including current maturities, was approximately $1.96 million.
- Cash used in investing was $24.76 million, including $10.54 million for property and equipment and $16.14 million for equity securities purchases. Financing provided $3.08 million, including TIA proceeds, partly offset by $2.82 million of common-stock repurchases.
Changes, outlook, and risks
- The sharp revenue decline chiefly reflects the absence of U.S. government sales in Q2 2022; the prior-year quarter included $27.36 million of such sales. First-half 2022 government sales were $15.73 million versus $65.14 million a year earlier. The company says additional government orders are uncertain.
- International revenue grew, but management notes international sales generally have lower per-unit revenue and may pressure overall margins. Overall unit sales fell 64.1% in Q2 and 25.5% in the first half.
- Q2 operating results were also affected by higher per-unit costs at lower production levels and a $3.90 million unrealized loss on equity securities. First-half unrealized investment loss was $0.57 million.
- Supply-chain and freight challenges continue, including Shanghai port closures delaying accepted international orders. About 91.2% of products in the first half were sourced from Chinese manufacturers. Management cited exposure to freight costs, tariffs, supplier availability, and geopolitical conditions.
- The company reduced its workforce by approximately 16% in June as government orders ended and facility expansion neared completion. New capacity may be underutilized if demand remains weak.
- The TIA provides up to approximately $81 million for domestic production expansion; management reported approximately $73.3 million received by August 1, 2022. The amended project completion date was August 29, 2022. A separate office expansion was expected to cost approximately $5.8 million, with about $4.2 million spent to date and substantial completion expected in October 2022.
- Management said cash, investments available for sale, and expected operating cash flow should cover short-term needs for at least 12 months and currently foreseeable long-term needs. No formal revenue or earnings guidance was provided.
- A lawsuit against former legal counsel remains pending. In July 2022, the court granted partial summary judgment against the company’s breach-of-fiduciary-duty claim, characterizing it as professional negligence or legal malpractice; defendants filed another summary-judgment motion in August. Trial was set for January 30, 2023.
Important facts for investors to verify
- Whether new government orders or other demand can replace pandemic-related contracts, and the pace of international orders.
- Progress, remaining commitments, and accounting treatment of TIA-funded expansion; clarify the project completion status after the amended deadline.
- Exposure to Chinese manufacturing, delayed shipments, freight costs, and potential effects on inventory and margins.
- Composition, liquidity, and market risk of the $26.87 million investment portfolio, particularly after the reported unrealized losses.
- Developments in the legal-malpractice litigation and the potential outcome or financial exposure; the filing does not provide a clear estimate of damages sought or loss exposure.
- Customer concentration: four significant customers represented 75.2% of first-half sales.